Key Performance
More- Earnings Score: 53
- Momentum Score: 17
- True Yield: N/A
- Financial Health Score: 0
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented the company's business and prospects. The lead plaintiff deadline is November 30, 2026.
10/21/2026, 6:56 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs.
10/18/2026, 3:04 PM • GlobeNewswire
Robbins LLP announced a class action lawsuit against Anavex Life Sciences Corp. for allegedly misleading investors about inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased AVXL securities between November 26, 2025 and August 28, 2026. The lead plaintiff deadline is November 30, 2026.
10/13/2026, 6:51 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and AST SpaceMobile to join securities class action lawsuits before upcoming deadlines. The lawsuits allege that these companies made false or misleading statements regarding their business operations, internal controls, and regulatory challenges. Investors who purchased securities during specified class periods may be entitled to compensation.
10/11/2026, 12:39 PM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Ardelyx, Inc., Anavex Life Sciences Corp., and AST SpaceMobile, Inc. during specified periods to join class action lawsuits. The firm alleges these companies made materially false statements regarding commercial performance and growth prospects. Investors have until November 16, 2026 to serve as lead plaintiffs.
10/11/2026, 12:26 PM • GlobeNewswire
Rosen Law Firm has filed a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented the company's business and prospects. The lead plaintiff deadline is November 30, 2026.
10/08/2026, 8:12 PM • GlobeNewswire
Kirby McInerney LLP has filed securities fraud class action lawsuits against Anavex Life Sciences Corp. for allegedly making false statements and failing to disclose inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased securities between November 26, 2025 and August 28, 2026. Anavex's stock declined significantly following disclosures about the CEO's termination, delayed SEC filings, and material weaknesses in internal controls.
10/07/2026, 6:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits. Tigo Energy faces allegations of false statements regarding an EG4 Electronics partnership (deadline: November 23, 2026). Fluence Energy is accused of misleading statements about production capabilities and revenue guidance (deadline: November 30, 2026). Anavex Life Sciences faces allegations of inadequate internal controls and understated regulatory challenges related to former CEO misconduct (deadline: November 30, 2026).
10/06/2026, 7:00 AM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. and Anavex Life Sciences Corp. on behalf of investors who purchased securities during specified periods. The Qfin lawsuit alleges defendants made false statements about business resilience and downplayed regulatory impacts. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.
10/05/2026, 6:49 PM • GlobeNewswire
A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements regarding adequate internal controls, understating regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresenting the company's business and prospects. Investors who purchased Anavex securities between November 26, 2025 and August 28, 2026 may be eligible to participate in the lawsuit.
10/05/2026, 4:59 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that the company made false and misleading statements regarding adequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.
10/02/2026, 2:48 PM • GlobeNewswire
A class action lawsuit has been filed against Anavex Life Sciences Corp. alleging securities fraud. The complaint claims the company made false statements about its business operations, lacked adequate internal controls, and understated regulatory challenges related to misconduct by former CEO Christopher Missling. The class period covers November 26, 2025 to August 28, 2026, and investors have until November 30, 2026 to request lead plaintiff status.
10/01/2026, 10:00 AM • GlobeNewswire
A securities class action lawsuit has been filed against Anavex Life Sciences Corp. (AVXL) for allegedly failing to disclose inadequate internal controls and regulatory challenges stemming from former CEO misconduct. The lawsuit covers securities purchased between November 26, 2025 and August 28, 2026. Investors have until November 30, 2026 to file as lead plaintiffs.
09/30/2026, 1:53 PM • GlobeNewswire
Rosen Law Firm has filed a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges the company made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff.
09/29/2026, 9:59 PM • GlobeNewswire
Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET
Anavex Life Sciences Corp. (AVXL) announced it has regained compliance with Nasdaq listing rules after filing outstanding Form 10-Qs for Q2 and Q3 2026. The company will host a conference call on September 9, 2026, where Interim CEO Terrie Kellmeyer will discuss clinical development strategy and priorities, with focus on Alzheimer's Disease programs.
09/08/2026, 8:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.